Muy contento de compartir nuestro estudio en @eBioMedicine sobre la vacuna LC16m8 durante el despliegue de la vacunación contra #mpox en Colombia 🇨🇴🇯🇵. Aportamos datos prospectivos sobre seguridad e inmunogenicidad, incluyendo a personas que viven con VIH. https://t.co/Ix7vtIByaL
MedTwitter, people often say that cefepime is stable to AmpC enzymes. However, I am having a very hard time finding published data evaluating this question. If you are aware of specific studies evaluating cefepime stability to AmpC, can you please share link or citation? Thanks!
🆕💥🟢Multicenter interventional trial using blood Mucorales PCR as a screening tool in high-risk hematology patients (MUCOPS) #IDXposts https://t.co/m61YmDlhCr
🚨 ACIN alerta sobre el desabastecimiento de antirretrovirales pediátricos en Colombia. Está en riesgo la prevención y el tratamiento del VIH en niños y niñas. Urgen soluciones inmediatas y sostenibles.
📢 Lea nuestro comunicado. @josemillanonate@DrIvanInfecto@Bacteriofago91
🆕💥🔴Culture results of heart valves resected from patients with active Enterococcus faecalis infective endocarditis undergoing heart valve surgery: insights into duration of antibiotic treatment required to achieve valve sterilisation.
📖 Infection | 2026 | Briggs et al.
#idxposts #IEWiki
https://t.co/lOldq3fbwx
🦴 La osteomielitis sigue siendo un reto frecuente en nuestros hospitales.
Diagnóstico tardío, cultivos inadecuados y antibi��ticos sin una estrategia clara pueden convertir una infección tratable en meses de enfermedad.
🇨🇴 En Colombia necesitamos hablar más de osteomielitis: diagnosticar mejor, obtener buenas muestras y tratar con precisión. @josemillanonate
“Candida auris es simplemente otra Candida”
Candida auris presenta desafíos particulares: puede propagarse en centros de salud, persistir en superficies y ser resistente a varios antifúngicos. Su detección y las medidas de prevención son fundamentales.
Descubre qué la hace diferente y comparte este video. @Adriana6Celis@josemillanonate #Micosis #FungalAwarenessWeek #Infectología #PiensaenHongosSalvaVidas
En 2015 en @blog_infecto habíamos hablado de esa epidemia de resistencia a la vacunación basada en una mentira planeada con interés de lucro por un hombre que perdió su licencia médica.
https://t.co/ZGANOOiQdk
45 years ago (June 5, 1981) the first description of what we now know as HIV/AIDS was published in @CDCMMWR The article describes Pneumocystis carinii pneumonia in 5 previously healthy men. Today, thanks to research and science, we have effective therapies & prevention @EmoryCFAR
Finally published
🆕🔥PANORAMIC RCT
+ CanTreatCOVID
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
Paxlovid did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection
https://t.co/9o52rwhDG5
Baloxavir more potent than Favipirqvir and Oseltamivir with faster clearance of influenza virus and resolution of fever but no difference in symptom improvement @ESCMID Global 2026. Abst 00015
Words matter!
It’s very frustrating that I’m still encountering the term “oral step-down” in major ID journals.
Let’s replace it with stewardship-aligned terms:
IV to oral switch
Oral transition
Streamlining
“Step-down” implies inferiority of oral antibiotics.
Time to stop using this term in ID journals—authors, editors, reviewers. #IDXposts
A questionable recommendation—ironically, the evidence cited in the guideline does not support it.
The panel appears to have selectively ignored the largest RCT (PHANTASi), citing low baseline mortality, while relying on smaller RCTs and observational studies that align with their position.
PHANTASi showed no mortality benefit across illness severities, yet the guideline authors argued the trial may not reflect the population they are recommending for (septic shock with delayed evaluation), making the recommendation speculative rather than evidence-based.
21. For adults with definite or probable sepsis and hypotension (i.e., septic shock) and anticipated in-hospital evaluation >60 min, we “suggest” administering antimicrobials in ambulance/flight (conditional recommendation, very low certainty evidence).
@BradSpellberg@PulmCrit@DrToddLee
Happy Eid on @ABsteward style
🆕⚡🔥Mini Review by 🌟 Dr.Patricia Simner
The shift from “MIC-Only” back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance
This minireview summarizes the evolution of CLSI guidance from early breakpoint establishment through the “MIC-only” era to the current antimicrobial resistance mechanism-driven framework. #IDXposts https://t.co/I2ocVOf4iU